MedTrace Logo

Value of Platelet-Rich Plasma in Post Severe Acute Respiratory Syndrome Coronavirus 2

NCT05395845 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2022-05-27

No results posted yet for this study

Summary

The study will be conducted to evaluate :

The efficacy of Platelet Rich plasma in treatment of smell disorders post severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via the growth factors involved in accelerating and enhancing healing.

Conditions

  • Anosmia

Interventions

BIOLOGICAL

platelets rich plasma

local ingection of platelets rich plasma

Sponsors & Collaborators

  • Aya abdelnasser hassani

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2022-12-01
Completion
2023-01-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05395845 on ClinicalTrials.gov